[go: up one dir, main page]

MX2013015147A - Procesos y compuestos intermediarios para producir azaindoles. - Google Patents

Procesos y compuestos intermediarios para producir azaindoles.

Info

Publication number
MX2013015147A
MX2013015147A MX2013015147A MX2013015147A MX2013015147A MX 2013015147 A MX2013015147 A MX 2013015147A MX 2013015147 A MX2013015147 A MX 2013015147A MX 2013015147 A MX2013015147 A MX 2013015147A MX 2013015147 A MX2013015147 A MX 2013015147A
Authority
MX
Mexico
Prior art keywords
intermediates
processes
azaindoles
producing
jak
Prior art date
Application number
MX2013015147A
Other languages
English (en)
Inventor
Adam Looker
Gerald J Tanoury
Young Chun Jung
Derek Magdziak
Brillie J Kline
Václav Jurcik
Beatriz Dominguez Olmo
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of MX2013015147A publication Critical patent/MX2013015147A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invención se refiere a procesos y productos intermediarios para la preparación de compuestos útiles como inhibidores de cinasas Janus (JAK).
MX2013015147A 2011-07-05 2012-07-03 Procesos y compuestos intermediarios para producir azaindoles. MX2013015147A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161504351P 2011-07-05 2011-07-05
US201261636296P 2012-04-20 2012-04-20
PCT/US2012/045431 WO2013006634A2 (en) 2011-07-05 2012-07-03 Processes and intermediates for producing azaindoles

Publications (1)

Publication Number Publication Date
MX2013015147A true MX2013015147A (es) 2014-03-27

Family

ID=46513874

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013015147A MX2013015147A (es) 2011-07-05 2012-07-03 Procesos y compuestos intermediarios para producir azaindoles.

Country Status (19)

Country Link
US (5) US8513414B2 (es)
EP (2) EP3141548B9 (es)
JP (3) JP2014520815A (es)
KR (1) KR20140058547A (es)
CN (2) CN106432311A (es)
AR (1) AR087069A1 (es)
AU (1) AU2012279046B2 (es)
BR (1) BR112014000115A2 (es)
CA (1) CA2839937C (es)
DK (1) DK3141548T3 (es)
ES (1) ES2804528T3 (es)
MX (1) MX2013015147A (es)
NZ (2) NZ714502A (es)
PL (1) PL3141548T3 (es)
PT (1) PT3141548T (es)
RU (1) RU2014103806A (es)
TW (1) TW201321378A (es)
WO (1) WO2013006634A2 (es)
ZA (1) ZA201400049B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005027825D1 (de) * 2004-03-30 2011-06-16 Vertex Pharma Als inhibitoren von jak und anderen proteinkinasen geeignete azaindole
SG10201405826RA (en) 2009-06-17 2014-12-30 Vertex Pharma Inhibitors of influenza viruses replication
CN106432311A (zh) 2011-07-05 2017-02-22 沃泰克斯药物股份有限公司 生产氮杂吲哚类的方法和中间体
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
WO2014201332A1 (en) 2013-06-14 2014-12-18 Vertex Pharmaceuticals Incorporated Pharmaceutical combinations useful for treating rheumatoid arthritis
RU2016110094A (ru) 2013-08-22 2017-09-27 Вертекс Фармасьютикалз Инкорпорейтед Изотопно-обогащенные азаиндолы
US9296727B2 (en) 2013-10-07 2016-03-29 Vertex Pharmaceuticals Incorporated Methods of regioselective synthesis of 2,4-disubstituted pyrimidines
PT3068776T (pt) 2013-11-13 2019-08-26 Vertex Pharma Inibidores da replicação de vírus da gripe
WO2015073481A1 (en) 2013-11-13 2015-05-21 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
JP6704416B2 (ja) * 2015-05-13 2020-06-03 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルスの複製の阻害剤を調製する方法
EP3294735B8 (en) 2015-05-13 2022-01-05 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
AU2016368317B2 (en) * 2015-12-09 2019-05-23 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication, application methods and uses thereof
CN105523986A (zh) * 2015-12-30 2016-04-27 江汉大学 一种外排泵抑制剂n-氢-2-芳基吲哚及其衍生物的合成方法
SG11201901983PA (en) 2016-09-09 2019-04-29 Hoffmann La Roche Process for preparation of 2-(6-nitropyridin-3-yl)-9h-dipyrido[2,3-b;3',4'-d]pyrrole
EP3558321B1 (en) 2016-12-23 2023-02-01 Felicitex Therapeutics, Inc. Derivatives of quinolines as inhibitors of dyrk1a and/or dyrk1b kinases
CN113242859B (zh) * 2018-12-24 2023-04-14 正大天晴药业集团股份有限公司 吡咯并嘧啶化合物的治疗用途及其固体药物组合物
CN113121452A (zh) * 2021-05-10 2021-07-16 甘肃堡昌化工有限公司 一种硫酸法尿嘧啶的精制工艺
CN113851244A (zh) * 2021-09-18 2021-12-28 浙江爱索拓科技有限公司 一种含放射性同位素碳-14废水的处理方法
CN113896716A (zh) * 2021-10-27 2022-01-07 浙江爱索拓科技有限公司 一种放射性同位素碳-14双标记甲磺酸伏美替尼合成方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721437D0 (en) 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
US20020065270A1 (en) 1999-12-28 2002-05-30 Moriarty Kevin Joseph N-heterocyclic inhibitors of TNF-alpha expression
JP2003532635A (ja) 2000-02-17 2003-11-05 アムジエン・インコーポレーテツド キナーゼ阻害薬
UY26942A1 (es) * 2000-09-20 2002-04-26 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
WO2003091246A1 (en) 2002-04-26 2003-11-06 Vertex Pharmaceuticals Incorporated Pyrrole derivatives as inhibitors of erk2 and uses thereof
AU2003241925A1 (en) 2002-05-31 2003-12-19 Eisai R&D Management Co., Ltd. Pyrazole compound and medicinal composition containing the same
CA2540828A1 (en) * 2003-09-30 2005-04-14 Scios Inc. Heterocyclic amides and sulfonamides
EP1712549B1 (en) 2004-01-30 2018-04-11 Nagase & Company, Ltd. Optically active quaternary ammonium salt having axial asymmetry and process for producing alpha-amino acid and derivative thereof with the same
UA87494C2 (en) * 2004-03-30 2009-07-27 Вертекс Фармасьютикалс Инкорпорейтед Azaindoles useful as inhibitors of jak and other protein kinases
DE602005027825D1 (de) * 2004-03-30 2011-06-16 Vertex Pharma Als inhibitoren von jak und anderen proteinkinasen geeignete azaindole
WO2006038001A1 (en) * 2004-10-06 2006-04-13 Celltech R & D Limited Aminopyrimidine derivatives as jnk inhibitors
US8921376B2 (en) 2005-05-20 2014-12-30 Vertex Pharmaceuticals Incorporated Pyrrolopyridines useful as inhibitors of protein kinase
CN101374839A (zh) * 2006-01-17 2009-02-25 沃泰克斯药物股份有限公司 适用作詹纳斯激酶抑制剂的吖吲哚类
EP2537849A3 (en) 2006-01-17 2013-04-03 Vertex Pharmaceuticals, Inc. Azaindoles useful as inhibitors of janus kinases
US8778977B2 (en) * 2006-06-30 2014-07-15 Sunesis Pharmaceuticals, Inc. Pyridinonyl PDK1 inhibitors
PT2050749T (pt) * 2006-08-08 2018-01-02 Chugai Pharmaceutical Co Ltd Derivado de pirimidina como inibidador de pi3k e sua utilização
WO2008076392A2 (en) 2006-12-14 2008-06-26 Vertex Pharmaceuticals Incorporated Compounds useful as protein kinase inhibitors
PT2207775E (pt) * 2007-11-05 2012-05-11 Novartis Ag Derivados de 4-benzilamino-1-carboxiacil-piperidina como inibidores de cetp úteis para o tratamento de doenças tais como hiperlipidemia ou arteriosclerose
MX2010008198A (es) * 2008-02-25 2010-08-23 Hoffmann La Roche Inhibidores de cinasa de pirrolopirazina.
SG10201405826RA (en) 2009-06-17 2014-12-30 Vertex Pharma Inhibitors of influenza viruses replication
CN106432311A (zh) 2011-07-05 2017-02-22 沃泰克斯药物股份有限公司 生产氮杂吲哚类的方法和中间体
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
EP2776036A1 (en) 2011-11-07 2014-09-17 Vertex Pharmaceuticals Incorporated Methods for treating inflammatory diseases and pharmaceutical combinations useful therefor
RU2016110094A (ru) 2013-08-22 2017-09-27 Вертекс Фармасьютикалз Инкорпорейтед Изотопно-обогащенные азаиндолы

Also Published As

Publication number Publication date
US20150284388A1 (en) 2015-10-08
CA2839937A1 (en) 2013-01-10
US8513414B2 (en) 2013-08-20
CA2839937C (en) 2020-11-03
JP6761448B2 (ja) 2020-09-23
US20150099884A1 (en) 2015-04-09
JP2014520815A (ja) 2014-08-25
CN103702998A (zh) 2014-04-02
RU2014103806A (ru) 2015-08-10
US20140309421A1 (en) 2014-10-16
DK3141548T3 (da) 2020-07-06
ES2804528T3 (es) 2021-02-08
JP2017002067A (ja) 2017-01-05
WO2013006634A3 (en) 2013-05-10
NZ619699A (en) 2016-03-31
PL3141548T3 (pl) 2020-09-07
CN106432311A (zh) 2017-02-22
EP3141548B9 (en) 2020-08-12
EP2729465A2 (en) 2014-05-14
US8796453B2 (en) 2014-08-05
AU2012279046B2 (en) 2017-08-31
AR087069A1 (es) 2014-02-12
WO2013006634A2 (en) 2013-01-10
AU2012279046A1 (en) 2014-01-23
EP3141548B1 (en) 2020-04-08
NZ714502A (en) 2017-04-28
US20130102782A1 (en) 2013-04-25
TW201321378A (zh) 2013-06-01
ZA201400049B (en) 2015-04-29
JP2018162314A (ja) 2018-10-18
PT3141548T (pt) 2020-07-10
WO2013006634A9 (en) 2013-03-21
BR112014000115A2 (pt) 2016-10-04
US8946425B2 (en) 2015-02-03
KR20140058547A (ko) 2014-05-14
US9090614B2 (en) 2015-07-28
US20130303764A1 (en) 2013-11-14
EP3141548A1 (en) 2017-03-15

Similar Documents

Publication Publication Date Title
MX2013015147A (es) Procesos y compuestos intermediarios para producir azaindoles.
MY201670A (en) Condensed imidazolylimidazoles as antiviral compounds
TW201240990A (en) Antiviral compounds
SI2697218T1 (sl) Postopek za pripravo spojin, koristnih kot zaviralci sglt2
AU2012213775A8 (en) 7-azaindole derivatives
WO2012107778A3 (en) Mutant pores
MX2014002442A (es) Inhibidores de pirrolopirazina cinasa.
SG176015A1 (en) Antiviral compounds
IN2014KN01491A (es)
MX2013015308A (es) Inhibidores de proteasoma y procesos para su preparacion, purificacion y uso.
PH12013502073A1 (en) Imidazopyridazines as akt kinase inhibitors
ZA201301799B (en) Process for the preparation of pan-cdk inhibitors of the formula (i),and intermediates of the preparation
NZ711192A (en) Process for making benzoxazepin compounds
IN2014KN01062A (es)
IN2014MN01671A (es)
EP2882744B8 (en) Process for the preparation of c-fms kinase inhibitors
HK1201067A1 (en) Sialic acid analogs
GB201107985D0 (en) Process
MX337610B (es) Proceso para la preparacion de (r)-2-acetamido-n-bencil-3-metoxipr opionamida e intermediarios de la misma.
MX2014002630A (es) Produccion de alcaloides sin el aislamiento de compuestos intermediarios.
PL2753625T3 (pl) Sposób wytwarzania związków zawierających grupę alfa-oksyfosforową dzięki zastosowaniu aktywatora
IN2012DN03040A (es)
MY168958A (en) Intermediates and processes for preparing compounds
HK1192754A (en) Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal